VERICEL CORP.

Vericel shares rose to a 52-week high of $48.41, bringing the market capitalization to about $2.44 billion. InvestingPro rates the stock as undervalued at the current level. Vericel reported robust Q1 2026 results with an EPS of -$0.12 (better than expected) and revenue of $68.4 million, drawing analyst attention and boosting investor sentiment. » More on de.investing.com

Soleus Capital disclosed a purchase of 1,785,079 Vericel shares in Q1, an estimated $63.4 million trade that leaves Vericel representing 3.32% of Soleus's 13F AUM. Vericel reported Q2 revenue of $63.2 million, up 20% year over year, driven by 21% growth in MACI; gross margin expanded to 74% and adjusted EBITDA rose to $13.4 million. The company ended the quarter with about $164 million in cash and investments, no debt, and received FDA clearance to begin a Phase 3 MACI study for ankle cartilage defects. » More on finance.yahoo.com

Vericel reported Q1 revenue of $68.4 million (+30% year-over-year), beating expectations. Growth was driven mainly by MACI ($56.4 million, +22%) and burns care ($12.0 million, +91%); adjusted EBITDA rose to $9.6 million. The company generated free cash flow of $15.1 million, is debt-free and holds about $211 million in cash and investments. Due to strong momentum, Vericel raised its 2026 revenue guidance to $326–336 million and reaffirmed its margin and EBITDA targets. » More on de.investing.com